The company
Genelux Corporation
GNLX · Nasdaq
GNLX stood above a rising 150-day average in 11 of the last 52 weekly readings, and has been out of that trend for the last 41 weeks. It is 11.4% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 41
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $649K
- Officials’ trades on record
- 0
- Institutions holding
- 71 (+4)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 11 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Yong YuChief Scientific Officer | sold | 9,683at $2.75 | 31 Aug 2026filed 2 Sep 2026 |
| Thomas ZindrickPresident and CEO | sold | 34,463at $2.67 | 31 Aug 2026filed 2 Sep 2026 |
| Joseph CappelloChief Technical Officer | sold | 10,257at $2.74 | 31 Aug 2026filed 2 Sep 2026 |
| Thomas ZindrickPresident and CEO | sold | 3,023at $2.95 | 4 Aug 2026filed 4 Aug 2026 |
| Joseph CappelloChief Technical Officer | sold | 653at $2.95 | 4 Aug 2026filed 4 Aug 2026 |
| Yong YuChief Scientific Officer | sold | 653at $2.94 | 4 Aug 2026filed 4 Aug 2026 |
| John W. SmitherDirector | sold | 12,000at $2.91 | 1 Jul 2026filed 2 Jul 2026 |
| Ralph SmallingHead of Regulatory | sold | 192at $2.93 | 3 Jun 2026filed 4 Jun 2026 |
| John ThomasDirector | sold | 10,000at $2.98 | 1 Jun 2026filed 2 Jun 2026 |
| Ralph SmallingHead of Regulatory | sold | 270at $2.98 | 11 May 2026filed 12 May 2026 |
| Thomas ZindrickPresident and CEO | sold | 2,798at $2.94 | 11 May 2026filed 12 May 2026 |
| Yong YuChief Scientific Officer | sold | 605at $2.97 | 11 May 2026filed 12 May 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| WOODWARD DIVERSIFIED CAPITAL, LLCadded · filed 28 Jul 2026 | 2,262,108$6.8M | +144,925+6.8% |
| VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026 | 1,677,724$5.0M | -17,756−1.0% |
| Bleichroeder LPunchanged · filed 13 Aug 2026 | 1,380,666$4.2M | 00.0% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 439,602$1.3M | +33,730+8.3% |
| GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026 | 439,213$1.3M | -14,548−3.2% |
| CM Management, LLCadded · filed 13 Aug 2026 | 400,000$1.2M | +150,000+60.0% |
| BANK OF AMERICA CORPadded · filed 14 Aug 2026 | 328,803$990K | +4,938+1.5% |
| VANGUARD FIDUCIARY TRUST COreduced · filed 13 Aug 2026 | 236,344$711K | -15,266−6.1% |
| FLPUTNAM INVESTMENT MANAGEMENT COreduced · filed 6 Aug 2026 | 231,405$697K | -49,499−17.6% |
| Global Retirement Partners, LLCnew · filed 6 Aug 2026 | 227,854$686K | +227,854 |
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.